Sierra Oncology Inc (SRRA) stock is down -68.35% over the last 12 months, and the average rating from Wall Street analysts is a Strong Buy. InvestorsObserver’s proprietary scoring system, gives SRRA stock a score of 42 out of a possible 100.
That score is chiefly influenced by a short-term technical score of 21. SRRA's score also includes a long-term technical score of 21. The fundamental score for SRRA is 85. In addition to the average rating from Wall Street analysts, SRRA stock has a mean target price of 3. This means analysts expect the stock to climb 500.00% over the next 12 months.
What's Happening with SRRA Stock Today
Sierra Oncology Inc (SRRA) stock is up 44.19% while the S&P 500 is down -0.58% as of 2:43 PM on Monday, Dec 2. SRRA is higher by $0.15 from the previous closing price of $0.35 on volume of 14,923,461 shares. Over the past year the S&P 500 is higher by 11.91% while SRRA is down -68.35%. SRRA lost -$0.74 per share in the over the last 12 months.